Revolutionary Usability of ZENEO® Auto-Injector in Critical Situations
In an impressive achievement, Crossject has successfully conducted a pivotal human factors study showcasing the usability of its ZENEO® Midazolam auto-injector. This innovative device is set to be marketed globally under the name ZEPIZURE®. The study emulated high-stress conditions akin to a chemical attack, demonstrating the auto-injector's reliability when it matters most.
Successful Assessment Under HAZMAT Conditions
The comprehensive HAZMAT dry-run involved 75 participants who effectively deployed 375 ZENEO® Midazolam auto-injectors while navigating through simulated hazardous environments. These daunting conditions included the challenges of wearing protective suits, which did not hinder the participants from handling the injectors proficiently. The study, conducted in rigorous conditions, validates the impressive design and functionality of the ZENEO® platform.
Understanding the Study Setup
Conducted in a controlled environment featuring auditory distractions like sirens and visual cues such as flashing lights, the study closely mimicked real-world emergency situations. The participants were attired in full-body CBRN (Chemical, Biological, Radiological, Nuclear) protective suits, designed specifically to simulate scenarios faced by first responders in critical incidents.
Impressive Results and Findings
Remarkably, all 75 untrained participants successfully activated the ZENEO® Midazolam on five mannequins representing individuals affected by neurotoxin exposure. The results are compelling, indicating the device's capability for rapid and efficient use by untrained individuals during high-pressure emergencies, reaffirming ZEPIZURE® as a life-saving solution.
Support from Government Agencies
Significantly, this human factors study received backing from the U.S. Department of Health and Human Services, awarded through BARDA (Biomedical Advanced Research and Development Authority) under a substantial contract. This government support underscores the critical nature of Crossject's mission in emergency preparedness.
CEO’s Insights on the Study
Patrick Alexandre, CEO of Crossject, expressed his satisfaction with the study's outcomes, which further highlights the ZENEO® auto-injector's adaptability under extreme conditions. "We are very pleased with the outcome of this HAZMAT study, which underscores again the exceptional usability of Crossject’s ZENEO® auto-injector - even when administered en masse by untrained personnel under extreme conditions," he stated.
The Future of ZENEO® and Crossject
Building upon previous studies, Crossject has consistently showcased its commitment to delivering vital medical solutions. In a 2022 study, the ZENEO® auto-injector demonstrated excellent usability among 60 untrained users, simulating situations such as epileptic crises. This trajectory of intensive research positions Crossject as a leader in the emergency pharmaceuticals sector.
About Crossject
Crossject SA is a rising specialty pharmaceuticals company focused on developing innovative medicines designed for urgent medical situations. The company harnesses its state-of-the-art ZENEO® needle-free auto-injector platform to facilitate the swift delivery of crucial emergency treatments. Currently, Crossject is advancing regulatory pathways for ZEPIZURE®, securing a notable $60 million contract with BARDA, indicative of its robust commitment to enhancing public health responses. The ZENEO® platform enables users, even those without training, to administer a wide array of essential medications rapidly and efficiently.
Frequently Asked Questions
What is ZENEO® Midazolam?
ZENEO® Midazolam is a needle-free auto-injector designed for emergency use, allowing for rapid medication delivery in critical situations.
How does the auto-injector work?
The device can be used easily by untrained caregivers, enabling them to inject medication directly into the muscle through clothing or bare skin in emergencies.
What was the purpose of the recent human factors study?
The study aimed to assess the usability of ZENEO® Midazolam under extreme stress and hazardous conditions to ensure reliability for first responders.
Who conducted the research study?
The study was conducted by Crossject, with substantial support from federal funding from the U.S. Department of Health and Human Services and BARDA.
What are the future prospects for Crossject?
Crossject aims to continue its development of out-of-the-box pharmaceuticals that can improve emergency medical responses, particularly with the ZENEO® platform.
